Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. The metric has seen a significant loss of -29.21% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -25.88%. Over the past 30 days, the price of PLX has leaped by -18.18%. And in the last five days, it has fallen by -4.55%.
In terms of market performance, Protalix BioTherapeutics Inc. had a somewhat inconsistent run in. The highest value for the stock in the past year was $3.55 on 05/05/23, while the lowest value was $1.21 on 03/25/24.
52-week price history of PLX Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Protalix BioTherapeutics Inc.’s current trading price is -64.51% away from its 52-week high, while its distance from the 52-week low is 4.56%. The stock’s price range for this period has been between $1.21 and $3.55. The Healthcare sector company’s shares saw a trading volume of about 0.28 million for the day, which was lower than the average daily volume of 0.33 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Protalix BioTherapeutics Inc. (PLX) has experienced a quarterly decline of -30.39% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 92.04M and boasts a workforce of 208 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.5211, with a change in price of -0.4300. Similarly, Protalix BioTherapeutics Inc. recorded 368,196 in trading volume during the last 100 days, posting a change of -25.44%.
PLX’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for PLX stands at 0.78. Similarly, the long-term debt-to-equity ratio is also 0.14.
PLX Stock Stochastic Average
As of today, the raw stochastic average of Protalix BioTherapeutics Inc. over the past 50 days is 11.58%. This is a increase compared to the raw stochastic average of the last 20 days, which was recorded at 11.58%. Additionally, the Stochastic %K and %D values for the company were 8.07% and 5.41%, respectively, over the past 20 days.
